Number of the records: 1
Steroide anionic compounds, method of their production, usage and pharmaceutical preparation involving them
- 1.
SYSNO ASEP 0471693 Document Type P - Patent R&D Document Type Patent or other outcome protected by special legislation Title Steroide anionic compounds, method of their production, usage and pharmaceutical preparation involving them Author(s) Chodounská, Hana (UOCHB-X) RID, ORCID
Šťastná, Eva (UOCHB-X) ORCID
Kapras, Vojtěch (UOCHB-X)
Kohout, Ladislav (UOCHB-X)
Borovská, Jiřina (UOCHB-X)
Vyklický ml., Ladislav (FGU-C) RID, ORCID, SAI
Valeš, Karel (FGU-C) RID, ORCID, SAI
Cais, Ondřej (FGU-C)
Rambousek, Lukáš (FGU-C) RID, ORCID
Stuchlík, Aleš (FGU-C) RID, ORCID
Bubeníková-Valešová, V. (CZ)Year of issue 2016 Possible third party use of the result A - Pro využití výsledku jiným subjektem je vždy nutné nabytí licence Royalty requested A - Poskytovatel licence požaduje licenční poplatek Patent no. or utility model no. or industrial design no. EP2435463 Date of the patent acceptance 12.10.2016 Name of the patent owner Ústav organické chemie a biochemie AV ČR, v. v. i. - Fyziologický ústav AV ČR, v. v. i. - Národní ústav duševního zdraví Code of the issuer name EPO_1 - European Patent Office Munich, The Hague, Berlin, Vienna, Brusselshttp://www.epo.org/ Current use A - Pouze udělený (dosud nevyužívaný) patent nebo patent využívaný jeho vlastníkem Language eng - English Keywords steroid anionic compounds ; central nervous system Subject RIV CC - Organic Chemistry Subject RIV - cooperation Institute of Physiology - Physiology Institutional support UOCHB-X - RVO:61388963 ; FGU-C - RVO:67985823 Annotation The presented invention applies to the compounds with general formula (I), where R1 stands for as mentioned previously in the compound specifications, the production process of the compounds with general formula (I), where R1 stands for as mentioned previously in the compound specifications, application of the compounds with general formula (I) in treatment of various diseases of central nervous system, in treatment of neuropsychiatric disorders related to imbalance of glutamatergic neurotransmitter system, ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, PTSD and other diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addictions, multiple sclerosis, epilepsy and gliomas. This invention further applies to the compounds with general formula (I) used for production of veterinary and human pharmaceutical preparations used in treatment of above mentioned diseases as well as in production of substances used in experimental research, analytic chemistry, dietary supplements or cosmetic preparations. Workplace Institute of Organic Chemistry and Biochemistry Contact asep@uochb.cas.cz ; Kateřina Šperková, Tel.: 232 002 584 ; Jana Procházková, Tel.: 220 183 418 Year of Publishing 2017 Electronic address https://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=2435463B1&KC=B1&FT=D&ND=4&date=20161012&DB=&locale=en_EP#
Number of the records: 1